Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market

JAMA Intern Med. 2021 Oct 1;181(10):1405-1407. doi: 10.1001/jamainternmed.2021.2769.

Authors

Joseph Levy¹, Zahra M Chowdhury², Mariana P Socal¹, Antonio J Trujillo²

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Abstract

This study explores the shifts in total US sales and net prices for all 3 insulin glargine products from quarter 1 of 2010 through quarter 2 of 2020.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biosimilar Pharmaceuticals* / classification
Biosimilar Pharmaceuticals* / economics
Biosimilar Pharmaceuticals* / therapeutic use
Diabetes Mellitus / drug therapy*
Drug Approval
Drug Costs*
Health Care Sector / trends
Humans
Hypoglycemic Agents / classification
Hypoglycemic Agents / economics
Hypoglycemic Agents / therapeutic use
Insulin Glargine* / classification
Insulin Glargine* / economics
Insulin Glargine* / therapeutic use
Interrupted Time Series Analysis
Marketing
United States

Substances

Biosimilar Pharmaceuticals
Hypoglycemic Agents
Insulin Glargine